On the morning of November 6, at the fourth China International Import Expo, the Administration of Hainan Boao Lecheng International Medical Tourism Pilot Zone (Lecheng Pilot Zone) and the world-famous medical product producer Danaher Group co-released the “Hainan Lecheng-- Mammotome Breast Tissue Biopsy Marker Real-world Study Program”.

Entrusted by Gu Gang, Party committee secretary and director of the Lecheng Pilot Zone Administration, Lv Xiaolei, Party committee member and deputy director and Peter Bootsma, the senior international affairs officer of Boao Lecheng Pilot Zone Administration attended the release ceremony.

Danaher is a global innovator of science and technology. In March 2021, Mammotome, a company under Danaher Group, performed the world’s first successful surgery with “Mammotome Resolve EX” two-way vacuum auxiliary breast rotary cutting system at Lecheng Pilot Zone, which was also the world’s first surgery performed since the establishment of Boao Lecheng Pilot Zone. Mammotome, GE Medicine and Boao Yiling signed a strategic cooperation agreement, and launched cooperation around breast tumor diagnosis and treatment schemes assisted by precision imaging technology so that the internationally leading technologies will be introduced into Lecheng Pilot Zone first to serve Chinese patients more accurately and efficiently.

On March 19, 2021, the world’s first application case of Mammotome Resolve EX system was released at Lecheng.

With the opportunity of China International Import Expo, Lecheng Pilot Zone and Danaher Group released the aforesaid program with an aim to further deepen their cooperation and achieve win-win development.

The new-generation Mammotome Resolve EX system’s real-world study at Lecheng will further improve the diagnosis and treatment of breast diseases in China, benefit over 40 million breast disease patients in China and create favorable conditions for the breast disease diagnosis and treatment in China to reach a world leading level.

Lv Xiaolei, Party committee member and deputy director of Lecheng Pilot Zone, said, “Danaher is Lecheng’s old friend. We thank Danaher for choosing us with a keen vision since the early stage. The real-world study program released this time is the extension and deepening of cooperation between us. At present, the medical industry’s ecosphere in Lecheng has been completed initially, which will develop at a faster speed in the future. We wish that Danaher can share the win-win fruits of Chinese market via the platform of Lecheng. We’re convinced that the reform and innovation of Lecheng will bring more development opportunities to internationally leading medical product producers like Danaher.”

Peng Yang, global vice president of Danaher Group and president of the Group in China, reviewed the cooperation history between Danaher and Lecheng Pilot Zone. He said, “Under the new pattern of dual circulation at home and abroad, we will update the localization strategy of Danaher in China once more. Together, we will empower the real-world study with the pioneering advantages of Lecheng and the open, strategic thinking of Danaher Group to speed up the marketing of our innovative products in China and benefit more Chinese patients.”

About Danaher Group

Danaher is a global innovator of science and technology. As a multinational corporation, Danaher owns many world-class brands in the fields of medical diagnosis, life science, water quality management and product identification, such as Beckman Coulter, Cepheid, Leica, Cytiva, Pall, Hach, Videojet and Pantone. In 2021, Danaher was ranked 130th among the Fortune 500, and rated by the magazine Fortune as second among the “Most Respected Medical Enterprises”. Chinese market is the largest market of Danaher beyond its home market in the US, accounting for over 13% of its global business.